Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia Leukemia (2005) We read with interest the article by Lundin et al 1 published in a recent issue of this journal. They studied immune reconstitution after subcutaneous Campath-1H therapy (target dose 30 mg) in previously untreated B-CLL patients. All lymphocyte subsets were significantly reduced during the study period and there was no correlation between the cumulative dose of alemtuzumab and the severity of immunosuppression.
We here confirm the data by Lundin et al in a group of heavily pretreated B-CLL patients who received intravenous Campath-1H therapy at 10 mg (target dose) three times weekly for a maximum of 10 weeks (total dose 300 mg). The patients were enrolled in an ongoing clinical trial investigating whether this lower dose of Campath-1H can reduce infectious complications while maintaining the same efficacy. Immunological data were available for 12 patients who received i.v. Campath-1H after a median of three lines of chemotherapy (Table 1) . Eight patients had previously undergone treatment with purine analogues. All patients included in this study were followed until disease progression after the end of Campath-1H.
Immunological parameters (total lymphocytes, CD3, CD4, CD8, CD19, CD16-56, IgG, IgM, IgA) were analysed before and after the end of the treatment on days 60, 120, 180 and 240. The treatment schedule included 3 mg of Campath-1H by i.v. infusion on day 1, and then to the target dose of 10 mg i.v. from day 3 until the end of study.
All flow cytometry and immunoglobulin assays were performed on freshly collected blood samples; the methodology has been extensively reported elsewhere. 2 Before treatment all lymphoid subsets, except for total lymphocytes and NK cells, showed median values within the normal range.
Total lymphocytes rapidly decreased during the treatment achieving median values below 1000/ml from day þ 60 to day þ 80, thereafter lymphocytes showed a mild trend toward recovery. Total T-lymphocytes (CD3) achieved nadir on day þ 60, from day þ 120 they showed a trend toward normalization reaching maximum levels at the end of the study (CD3 765/ml on day þ 240). The median values of T-helper subsets rapidly decreased reaching nadir on day þ 60 (CD4 117/ml), thereafter a mild recovery was noticed that achieved maximum levels at the end of the study with median values below the normal range. CD8 T-suppressor lymphocytes, after an initial decrease, at the end of Campath-1H treatment showed a mild increase achieving maximum levels (366/ml) on day þ 180 and remained stable until the end of the study. Median values of effector cells CD16/56 lymphocytes (NK cells) before and after treatment were above the normal range, except for days þ 120 to þ 180 when they were within the normal range. All classes of immunoglobulins (IgG, IgA, IgM) during the study showed median values within the normal range (Table 2) .
We agree with Lundin et al with regard to the profound degree of immunosuppression after Campath-1H therapy.
Although our patients were heavily pretreated before Campath-1H, we demonstrated that lymphocytes subsets were into the normal range before therapy with Campath-1H administered at 10 mg i.v. for a maximum cumulative dose of 300 mg, which is markedly less than the lower dose used by Lundin et al (median cumulative dose 1362 mg range 343-1573).
The lymphocyte recovery after alemtuzumab therapy was similar to our previously published data concerning the immune recovery after autologous transplantation.
In both studies high values of NK cells, immediately after Campath-1H therapy or autologous transplant, might provide a possible defense against pathogens, in a period in which the lack of cooperation between T and B cells results in the inability to produce antibodies. [3] [4] [5] [6] [7] The normal levels of immunoglobulin after alemtuzumab therapy could be explained by the cooperation between normal residual T and B cells, which are depressed after transplant because of the conditioning regimen. 4 As expected, in our study the follow-up was shorter than in Lundin's series because disease progression in these heavily pretreated patients was more rapid.
Thus, we conclude that the previous chemotherapy, reduced cumulative dose (median cumulative dose of 300 mg vs 1362 mg) and administration route (standard dose of 10 mg i.v. vs 30 mg s.c.) of Campath-1H therapy do not influence the longlasting depletion of major blood lymphocyte subsets after the end of the treatment. Multiple myeloma (MM) is an incurable B-cell malignancy that is characterized by both relapsing and refractory disease. Therapeutic strategies are needed to overcome drug resistance and to improve patient outcomes for this difficult-to-treat patient population. Arsenic trioxide has been shown to be effective in the treatment of acute promyelocytic leukemia in newly diagnosed disease, 1,2 as well as in refractory/relapsed disease. Normal range
